RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.